Trial
NCT03709706
Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
GlaxoSmithKline
Collaborators
Merck Sharp & Dohme LLC
Condition
Neoplasms
Intervention
Lete-cel
Why stopped
The study was terminated for reasons pertaining to feasibility
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-02-23